ArticleFrontiers in microbiology2021
OXA-484, an OXA-48-Type Carbapenem-Hydrolyzing Class D β-Lactamase From
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- First Report of aAntibiotics (Basel, Switzerland) · 2026Article
- Role of Mobilome in Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- The combination of active partitioning and toxin-antitoxin systems is most advantageous for low-copy plasmid fitness.Nature communications · 2025Article
- Deciphering the genetic context of the emerging OXA-484-producing carbapenem-resistant Escherichia coli from ST167 high-risk clone in the United Arab Emirates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- OXA-48-like carbapenemases inEmerging microbes & infections · 2024Article
- Oxacillinase-484-Producing Enterobacterales, France, 2018-2023.Emerging infectious diseases · 2024Article
- Molecular, Genetic, and Biochemical Characterization of OXA-484 Carbapenemase, a Difficult-to-Detect R214G Variant of OXA-181.Microorganisms · 2024Article
- Emergence of OXA-48-like producingEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Emergence of OXA-484-ProducingInfection and drug resistance · 2023Article
- Klebsiella Species and Enterobacter cloacae Isolates HarboringMicrobiology spectrum · 2022Article
- Current and Emerging Treatment Options for Multidrug ResistantAntibiotics (Basel, Switzerland) · 2022Review
- Emergence of TnAntimicrobial agents and chemotherapy · 2022Article
- Repatriation of a patient with COVID-19 contributed to the importation of an emerging carbapenemase producer.Journal of global antimicrobial resistance · 2021Article
- Systematic Comparison of Three Commercially Available Combination Disc Tests and the Zinc-Supplemented Carbapenem Inactivation Method (zCIM) for Carbapenemase Detection inJournal of clinical microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OXA-48-like carbapenemases are among the most frequent carbapenemases in Gram-negative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.